NASDAQ · IMTX
Immatics N.V.
$6.99-$0.32 (-4.39%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.68% below the high.
Loading market information…
NASDAQ · BLPH · USD
Stock price, earnings
Quote as of Dec 18, 2024, 05:51 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bellerophon Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bellerophon Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is actively advancing the development of INOpulse across multiple indications: Currently, INOpulse is undergoing a Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease. It has successfully completed a Phase 2a trial for pulmonary hypertension tied to chronic obstructive pulmonary disease. Furthermore, a Phase 2 dose escalation stage has concluded for pulmonary hypertension associated with sarcoidosis. The company is also exploring INOpulse's potential for chronic thromboembolic pulmonary hypertension and PH stemming from high altitude sickness. Founded in 2009, the enterprise, originally known as Ikaria Development LLC, adopted the Bellerophon Therapeutics, Inc. name in January 2014. Its corporate headquarters are situated in Warren, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 |
|---|
| Mar 31, 2022 |
| -$0.45+25.0% vs estimate |
| $0.00 |
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.99-$0.32 (-4.39%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.68% below the high.
$0.90$0.00 (0.0%)
Atlantic International Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.86% below the high.
$0.88-$0.04 (-4.83%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.04% below the high.
$0.07-$0.10 (-60.05%)
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
$0.50$0.00 (0.0%)
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
$0.37$0.00 (0.0%)
Seelos Therapeutics, Inc.: Healthcare · Biotechnology.
$0.16+$0.02 (+12.4%)
Virios Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.31+$0.08 (+36.94%)
Akerna Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
